| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA585: Ocrelizumab for treating primary progressive multiple sclerosis |
|
Medicine details |
|
| Medicine name | ocrelizumab (Ocrevus®) |
| Formulation | intravenous infusion |
| Reference number | 1096 |
| Indication | First-line treatment of primary progressive multiple sclerosis |
| Company | Roche Products Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 08/02/2018 |
| NICE guidance | TA585: Ocrelizumab for treating primary progressive multiple sclerosis |